Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 4 selected

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 1 to 10 of 1594

TitleReference numberPublishedLast updated
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentTA1164
Nusinersen and risdiplam for treating spinal muscular atrophyTA1162
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)TA1163
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatmentTA1159
Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinomaTA1160
Sotatercept for treating pulmonary arterial hypertensionTA1161
Givinostat for treating Duchenne muscular dystrophy in people 6 years and overTA1157
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancerTA1158
Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapyTA1156
Rozanolixizumab for treating antibody-positive generalised myasthenia gravisTA1155

Results per page

  1. 10
  2. 25
  3. 50
  4. All